Sosei Group News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.08.21	Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021 (PR Newswire)
12.08.21	Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021 (PR Newswire)
06.07.21	Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration (PR Newswire)
06.07.21	Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration (PR Newswire)
05.06.20	Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma (PR Newswire)
05.06.20	Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma (PR Newswire)
07.11.18	Sosei Enters Collaboration to Combine Pioneering DNA Technologies With StaR® Technology to Accelerate New Drug Discovery (PR Newswire)
07.11.18	Sosei Enters Collaboration to Combine Pioneering DNA Technologies With StaR® Technology to Accelerate New Drug Discovery (PR Newswire)
01.11.18	Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei (PR Newswire)
01.11.18	Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei (PR Newswire)
18.04.18	Sosei Confirms New Data Demonstrating AZD4635, a Novel A2A Receptor Antagonist, Induces Anti-Tumor Immunity Alone and in Combination With Anti-PD-L1 in Preclinical Models (Businesswire)
13.03.18	Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches (Businesswire)
08.02.18	Sosei Provides an Update on Its Immuno-Oncology Clinical Program with AstraZeneca (Businesswire)
02.02.18	Sosei Announces Restatements of Previously Issued Quarterly and Full Year Accounts (Businesswire)
19.01.18	Changes in Executive Management at Sosei (Businesswire)
09.11.17	Sosei to Advance Clinical Development in Japan of HTL0018318 in Patients with Dementia with Lewy Bodies (DLB) (Businesswire)
08.11.17	Strategic Minority Investment Company MiNA Therapeutics Enters Into Collaboration and Licensing Agreement With Boehringer Ingelheim (Businesswire)
05.10.17	Heptares Founder Richard Henderson Receives Nobel Prize in Chemistry 2017 for Pioneering Work in cryo-EM for Visualising Biological Structures (Businesswire)
20.09.17	Sosei meldet die Besetzung der wichtigen Positionen des Head of Investor Relations and Corporate Communications sowie des Group Financial Controller (Businesswire)
01.09.17	Sosei: First Subject Dosed in Phase1 Clinical Study of Novel Selective Muscarinic M4 Agonist in Development to Treat Major Symptoms of Alzheimer's Disease (Businesswire)
30.11.16	Sosei Subsidiaries Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-focused Drug Discovery and Development (Businesswire)
10.11.16	Sosei Subsidiaries Heptares and Jitsubo to Develop Novel GPCR-Targeting Peptide Candidates for Severe Gastro-Intestinal Disorders (Businesswire)
06.07.16	Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment from AstraZeneca to Heptares (Businesswire)
07.04.16	Sosei Subsidiary Heptares and Allergan Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders (Businesswire)
28.09.15	Sosei Subsidiary Heptares Awarded $5.5 Million Research & Development Grant from the US National Institute on Drug Abuse (Businesswire)
06.08.15	Sosei Subsidiary Heptares and AstraZeneca Enter Agreement to Develop Novel Immuno-Oncology Treatments for a Range of Cancers (Businesswire)
23.02.15	Sosei Acquires Heptares Therapeutics for up to USD 400 million (Businesswire)
27.07.13	First in Class Once-Daily Dual Bronchodilator Ultibro® Breezhaler® (QVA149) Gains Positive CHMP Opinion for the Treatment of COPD (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Sosei Group Corp

Aktien Top/Flop

Meistgelesene Nachrichten